Company Overview and News

 
SC orders fresh resolution process against Jaypee Infra

2018-08-10 freepressjournal.in
Mumbai : In a setback to the Jaypee Group, the Supreme Court on Thursday ordered re-commencement of resolution process against Jaypee Infratech and barred the firm, its holding company and their promoters from participating in the fresh bidding process.
532532 533207 JPINFRATEC JIPKY JPASSOCIAT

 
Home for family is a basic ‘human yearning’, says Supreme Court

2018-08-09 freepressjournal.in
New Delhi: The Supreme Court today observed that having a house for a family was a “basic human yearning” wherein hard earned money was invested in the hope of obtaining a roof over their heads. A bench headed by Chief Justice Dipak Misra made the observation in a verdict in which the apex court ordered re-commencement of resolution process against Jaypee Infratech Ltd (JIL) and barred the firm, its holding company and their promoters from participating in the fresh bidding process.
532532 533207 JPINFRATEC JIPKY JPASSOCIAT

 
SC asks National Company Law Tribunal to deal with insolvency proceedings against Jaypee Infratech Ltd

2018-08-09 freepressjournal.in
New Delhi: In a setback to the Jaypee group, the Supreme Court today asked the National Company Law Tribunal (NCLT), Allahabad, to deal with the insolvency proceedings against Jaypee Infratech Ltd (JIL) and barred the group or its promoters from participating in the fresh bidding process.
533207 JPINFRATEC

 
Rajya Sabha Deputy Chairman election: NDA candidate Harivansh Narayan Singh elected with 125 votes

2018-08-09 freepressjournal.in
New Delhi: NDA candidate and JD(U) member Harivansh Narayan Singh was today elected as Rajya Sabha Deputy Chairman, defeating opposition’s B K Hariprasad. Rajya Sabha Chairman M Venkaiah Naidu initiated the process of the election by calling for division of votes in the House. While Harivansh Narayan Singh secured 125 votes, Hariprasad got 105.
533207 JPINFRATEC

 
NCLT to hear insolvency proceedings against Jaypee

2018-08-09 livemint
New Delhi: In a setback to the Jaypee group, the Supreme Court on Thursday asked the National Company Law Tribunal (NCLT), Allahabad, to deal with insolvency proceedings against Jaypee Infratech Ltd (JIL), and barred the group and its promoters from participating in fresh bidding process.
533207 500116 JPINFRATEC IDBI

 
Ill-timed, poorly assessed loan to Jaypee caused over Rs 1,000 crore NPA: CAG raps IIFCL

2018-08-07 moneycontrol
An ill-timed and loosely assessed loan of Rs 900 crore to Jaypee Infratech Ltd hit the Yamuna Expressway Project over a period of time, causing a build-up of bad assets worth over Rs 1,000 crore on the books of IIFCL, a CAG report observed.
533207 JPINFRATEC

 
Bankruptcy code amendments offer some hope to troubled home buyers

2018-08-02 livemint
New Delhi: Granting home buyers financial creditor status and opening up new streams of finance for completing halted projects under the amended bankruptcy code are set to offer relief to consumers.
533207 JPINFRATEC

 
Jaypee Infratech Q1 loss widens to Rs 298 cr

2018-07-31 moneycontrol
Bankruptcy-bound Jaypee Infratech today reported a net loss of Rs 298.33 crore for the first quarter this fiscal. Its net loss stood at Rs 44.78 crore in the year-ago period, the company said in a regulatory filing.
533207 500116 JPINFRATEC IDBI

 
Jaiprakash Associates posts Rs 285 cr loss for Q1 FY19

2018-07-30 moneycontrol
Debt-ridden Jaiprakash Associates Ltd (JAL) today reported a standalone net loss of Rs 285.02 crore for the first quarter of this financial year. Its net profit stood at Rs 764.99 crore in the year-ago period, the company said in a regulatory filing.
532532 533207 500116 JPINFRATEC JIPKY IDBI JPASSOCIAT

 
Jaypee Infratech Limited - Press Release

2018-07-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533207 JPINFRATEC

 
Jaypee Infra liquidation will serve no purpose: SC

2018-07-20 freepressjournal.in
New Delhi : Liquidation of real estate firm Jaypee Infratech (JIL) would not “serve” the purpose of either home buyers, financial institutions or the promoters, the Supreme Court on Thursday said.
532532 533207 JPINFRATEC JIPKY JPASSOCIAT

 
Jaypee-homebuyers case: Supreme Court reserves verdict on course of action

2018-07-19 livemint
New Delhi: A Supreme Court bench headed by Chief Justice Dipak Misra on Thursday reserved its verdict on the course of action in the Jaypee Infratech Ltd (JIL)- homebuyers litigation, after the corporate insolvency resolution period for JIL expired in May this year.
532532 533207 500116 JPINFRATEC JIPKY IDBI JPASSOCIAT

 
JAL seeks approval to sell assets to deposit Rs 600 cr

2018-07-19 freepressjournal.in
New Delhi : Jaiprakash Associates (JAL) on Monday told Supreme Court it would deposit Rs 600 crore more to refund the home buyers if it was allowed to dispose of its identified assets, including a cement plant at Rewa in Madhya Pradesh.
532532 533207 JPINFRATEC JIPKY JPASSOCIAT

 
SC to hear Jaypee home buyers’ plea on Mon

2018-07-19 freepressjournal.in
New Delhi : The Supreme Court on Friday listed for final hearing on July 16 the pleas of hassled home buyers registered with Jaiprakash Associates (JAL) saying that it would exclusively deal with their grievances and the “capability” of realty firm to refund money to them.
532532 533207 JPINFRATEC JIPKY JPASSOCIAT

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

6h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...